Erdafitinib has a biomarker-defined role in urothelial carcinoma, a cancer that commonly begins in the urinary tract lining and most frequently involves the bladder.
U.S. indication
Current U.S. BALVERSA labeling indicates erdafitinib for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Patients are selected using an FDA-approved companion diagnostic.
The current U.S. label also states that BALVERSA is not recommended for patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.
European Union indication
The EMA currently describes Balversa as monotherapy for adults with unresectable or metastatic urothelial carcinoma containing susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic setting.
Why the biomarker matters
Erdafitinib is not intended for every person with urothelial carcinoma. Treatment selection depends on the presence of a susceptible FGFR3 alteration.
The diagnostic result must therefore be interpreted in the context of the approved companion diagnostic and applicable regulatory criteria.
Treatment setting
Erdafitinib is used in advanced disease rather than as a general treatment for all stages of bladder cancer.
The precise treatment sequence can depend on:
- Tumor molecular findings
- Previous systemic therapy
- Immunotherapy exposure
- Disease progression
- Regulatory jurisdiction
- Patient health and organ function
- Tolerability
Clinical evidence
The phase 3 THOR study evaluated erdafitinib against investigator-choice chemotherapy in patients with advanced or metastatic urothelial carcinoma and susceptible FGFR alterations following prior treatment that included an anti-PD-1 or anti-PD-L1 agent. In the published cohort, median overall survival was 12.1 months with erdafitinib versus 7.8 months with chemotherapy, while median progression-free survival was 5.6 versus 2.7 months.
These results apply to the studied population and should not be interpreted as a prediction of an individual patient’s outcome.
Investigational uses
Research has examined erdafitinib in additional FGFR-altered cancers and treatment settings. Clinical investigation does not automatically establish regulatory approval.